Cisen Pharmaceutical (603367.SH) Subsidiary's Drug Loteprednol Etabonate and Tobramycin Ophthalmic Suspension Approved for Marketing as First Generic
Cisen Pharmaceutical (603367.SH) announced that recently, its subsidiary Shandong Cisen Fodu Pharmaceutical Co., Ltd. ("Fodu Pharmaceutical") received the Drug Registration Certificate for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension approved and issued by the National Medical Products Administration.
Cisen Pharmaceutical (603367.SH) announced that recently, its subsidiary Shandong Cisen Fodu Pharmaceutical Co., Ltd. ("Fodu Pharmaceutical") received the Drug Registration Certificate for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension approved and issued by the National Medical Products Administration.
Loteprednol Etabonate and Tobramycin Ophthalmic Suspension is classified as a Category 4 chemical drug, primarily indicated for the treatment of steroid-responsive ocular inflammation, and its accompanying or potential ocular surface bacterial infections. The registration application for Fodu Pharmaceutical's Loteprednol Etabonate and Tobramycin Ophthalmic Suspension was first accepted in 2025, and this approval marks its launch as the first generic in China.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






